GlassScriptPhysician profile
William Knubley
NPI 1346269180
$25,801.61
in general payments reported to CMS, 2019-2025
56 companies · $17.34 in 2025
The $17.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,753 · 2020: $4,810 · 2021: $8,135 · 2022: $5,409 · 2023: $3,050 · 2024: $1,628 · 2025: $17.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,693.39 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $7,713.59 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,511.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,682.25 | 2019-2024 | |
| Abbvie INC. | $1,559.34 | 2021-2024 | |
| Amgen INC. | $1,049.22 | 2019-2023 | Aimovig |
| Ucb, INC. | $919.99 | 2019-2024 | Briviact, Fintepla |
| Sk Life Science, INC. | $796.49 | 2020-2024 | Xcopri |
| Eisai INC. | $665.58 | 2019-2024 | |
| Genzyme Corporation | $651.67 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $631.85 | 2019-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $602.26 | 2020-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $597.89 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Mdd US Operations, LLC | $508.81 | 2019-2025 | Gocovri, Xadago, Apokyn |
| Amneal Pharmaceuticals LLC | $495.97 | 2019-2023 | Rytary |
| Biogen, INC. | $452.60 | 2019-2024 | Vumerity, Tysabri, Skyclarys |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Knubley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.